Xiuning Le MD PhD
@LeXiuning
Followers
2K
Following
3K
Media
117
Statuses
261
Associate Professor Thoracic Head and Neck Medical Oncology MD Anderson Cancer Center
Houston, TX
Joined March 2020
🎉🎉🎉We celebrate #FDA approval of #zongertinib as the first TKI in #HER2-mutant #NSCLC 🎊 🎂 🌺 🩷 .👉 ORR 71% .👉 Duration of Response 14.1 months .👉 PFS 12.4 months .👉 Well-tolerated at 120mg dose.📖 In previously treated patients without prior anti-HER2 targeted therapies
3
18
102
Leave it to @BalazsHalmosMD to stay 1. current 2. informative and absolutely 3. hilarious 😂 . Amazing conversations happening here at #BTGLung2025 discussing the perioperative early stage NSCLC treatment landscape! #ColdplayConcert @NarjustFlorezMD @DrEdKim
0
3
28
Fantastic work together with @Alfdoc2 @jillfeldman4 and my global colleagues. Now we have identified clinical and molecular poor prognostic factors, we just have to push forward to improve outcomes for those patients. @MDAndersonNews @lungoncdoc @OncoViews @oncodaily.
Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 thanks to all the co-authors, great team.
0
8
29
📖 New Online: "#AI in #LungCancer Clinical Translation" — a collaborative effort between my group Dr. Erjia (EJ) Zhu @ErjiaZ96533 and Dr. @JiaWu_PhD. We share insights through the lens of thoracic oncologists navigating this evolving landscape. 🔗 .👉
3
6
27
Thank you @DAVAOnc @vinayjai for another successful Lung Summit meeting! Nice to hangout and exchange scientific ideas in the beautiful island Kona with Drs. Jay Zhang, Haniel Araujo, @FSkoulidis, John Heymach, Jia Wu, @lungoncdoc @MDAndersonNews. Amazing nature.
0
4
32
RT @jennifermarksmd: Very important study planned by Dr. @LeXiuning :A phase I/lb study of concurrent intrathecal and intravenous amivantam….
0
6
0
I am extremely thankful for the entire RAMOSE trial team, co-investigators, @hoosiercancer HCRN , clinical research staff, and pts/families to complete this large multi-center randomized investigator-initiated trial (IIT) in #EGFR #lungcancer. We will report OS and other.
At #DAVALung, Dr. Xiuning Le (@LeXiuning, @MDAndersonNews) presented RAMOSE trial updates: ramucirumab + osimertinib improved PFS to 22.3m vs 16.1m with osimertinib alone (HR 0.56) in EGFR-mutant NSCLC. Benefit consistent across subgroups; toxicity manageable.
1
5
29
We have three TKIs: firmonertinib, sunvozertinib, and zipalertinib, with FDA breakthrough designation (BTD) for EGFR Ex20ins NSCLC patients. We will change the SoC landscape soon for this patient population! @EGFRResisters @Exon20Group @lungoncdoc I cannot wait to debate among.
#NSCLC treatment with Firmonertinib! Dr. @LeXiuning of @MDAndersonNews shares data in #EGFRex20 & PACC NSCLC—ORR 78.6% in 1L ex20ins, 63.6% in 1L PACC, intracranial ORR 55.6% in CNS mets. FAVOR & PACC trials shaping next steps. #DAVALung #Oncology #LungCancer
2
13
42
It is such a treat to discuss science with thoracic colleagues in the beautiful island of Kona, Hawaii. @lungoncdoc @jennifermarksmd @OncoViews @oncodaily @MDAndersonNews.
Targeting HER2 Exon 20 in #NSCLC: Dr.@LeXiuning (@MDAndersonNews) shares updated data on sevabertinib (BAY 2927088) with 60.5% ORR and 8.7 mo DoR in pretreated pts, and 90% ORR in YVMA+ tumors, reinforcing its mutation-selective activity and ongoing Phase III plans. #DAVALung
0
3
23
💐💐💐Congratulations, Dr. @KelseyPanMD, on your graduation from the #Hematology/#Oncology Fellowship at MDACC @MDAndersonNews.It’s been a pleasure working with you, and I’m truly excited to now call you a fellow thoracic oncologist. I look forward to collaborating with you on
4
2
49
❤️ ✈️ Feeling hopeful and joyful as I leave Chicago after a productive but exhausting #ASCO25 . 💐 🎊 On the final evening, we celebrated the 10-year anniversary of #osimertinib approval—an incredible milestone—surrounded by friends and colleagues from around the world. I'm
5
6
66
#ASCO25 with friends and colleagues from academia and industry, from all parts of the globe, during #lungcancer poster session. @HHorinouchi @geoff_oxnard @LaurenByersMD @MDAndersonNews Drs. TimYap, MartinReck, MolliLi AlexSpira.
0
3
23
BAY88 has its name now, sevabertinib 😀. We are actively enrolling globally for HER2-activating mutation treatment-naive NSCLC patients.
🆕 #ASCO25 🆙.☑️#LCSM Poster.🔥SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations.🎙️ @LeXiuning.📌Poster Bd127b, Abstr TPS8648.🔢NCT06452277.@OncoAlert @ASCO @Larvol .
1
11
28
BN-39643 represents the newest concept of EGFR TKI, higher potency than osimertinib, CNS penetration, covering classical, C797S, PACC, and ex20 mutations, so it prevents all EGFR dependent resistance.
🆕 #ASCO25 🆙.☑️#LCSM Poster.🔥SOLARA: Phase 1/2, FIH study of BH-30643 in pts with NSCLC harboring EGFR and/or HER2-m.🎙️ @LeXiuning @HHorinouchi.📌Poster Bd135a, Abstr TPS 8663.🔢NCT06706076.@OncoAlert @ASCO @EGFRResisters @Larvol.
1
18
51
NVL-330 represents the next generation of HER2 TKI. High CNS penetration, high potency, sparing EGFR wt.
🆕 #ASCO25 🆙.☑️#LCSM Poster.🔥NVL-330, a selective HER2 tyrosine kinase inhibitor, in pts with advanced or metastatic HER2-altered NSCLC: The phase 1 HEROEX-1 study.🎙️ @LeXiuning.📌Poster Bd136a, Abstr TPS8665.🔢NCT06521554.@OncoAlert @ASCO @Larvol .
1
5
15
#AACR25, Dr. Simon Heek presented "Association of baseline ctDNA #EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinibversus osimertinibin EGFR+ #LungCancer. @MDAndersonNews @lungoncdoc .👉Baseline assessment of #EGFR
0
10
29